Full Press Release Details
SAN FRANCISCO , Feb. 26, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March 4, 2024 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time .
The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/ . The web broadcast of the conference call will be available for replay through April 4, 2024 .
To access the conference call, please pre-register at Nektar Earnings Call Registration . All registrants will receive dial-in information and a PIN allowing them to access the live call.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in immunology and oncology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California , with additional manufacturing operations in Huntsville, Alabama . Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com .
Vivian Wu of Nektar Therapeutics 628-895-0661
David Rosen of Argot Partners (212) 600-1902 [email protected]
SOURCE Nektar Therapeutics